Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dana-Farber Cancer Institute
With
Brigham and Women's Hospital
National Institutes of Health (NIH)
* Leukemia cells will be collected by one or more of the following methods: 1)Routine blood draw 2)Bone marrow aspirate 3) Leukapheresis. The physician and study staff will determine which of the methods above is best suited for each participant.
* After collection, the leukemia cells will be transported to the Cell Manipulation Core Facility (CMCF) at the Dana-Farber Cancer Institute, where they will be frozen until the time of vaccine administration.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with AML will be eligible for banking at the time of relapse or primary induction failure or at the time of AML diagnosis they are 60 years of age or older, AML arising out of background MDS or MPD or AML known with high risk cytogenetics
Patients with MDS-RAEB-1 or RAEB-II, CMML-1 or CMML-II
Patients must have \>5% blast in bone marrow or peripheral blood
ECOG Performance Status 0-2
Age greater than or equal to 18 years
Reasonable likelihood, in the physician's opinion, that the patient will be a candidate for allogeneic stem cell transplant